Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Expected to Rise, HC Wainwright Analyst Says

Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by stock analysts at HC Wainwright from $130.00 to $158.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 45.06% from the stock’s current price.

Several other equities research analysts have also weighed in on the stock. Raymond James Financial reiterated a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a report on Wednesday. Wedbush boosted their price target on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $124.27.

Dianthus Therapeutics Stock Down 0.9%

Dianthus Therapeutics stock opened at $108.92 on Thursday. The business’s 50-day simple moving average is $94.72 and its 200 day simple moving average is $80.65. The stock has a market cap of $5.95 billion, a price-to-earnings ratio of -26.25 and a beta of 1.22. Dianthus Therapeutics has a 12-month low of $18.08 and a 12-month high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. As a group, sell-side analysts expect that Dianthus Therapeutics will post -3.94 EPS for the current year.

Insider Transactions at Dianthus Therapeutics

In related news, SVP Adam M. Veness sold 30,000 shares of the stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the transaction, the senior vice president directly owned 30,000 shares in the company, valued at approximately $2,424,000. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $362,480. The trade was a 86.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 253,779 shares of company stock valued at $25,931,495. 3.02% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of large investors have recently bought and sold shares of DNTH. PNC Financial Services Group Inc. boosted its stake in shares of Dianthus Therapeutics by 0.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after buying an additional 139 shares during the last quarter. First Horizon Corp acquired a new stake in shares of Dianthus Therapeutics in the first quarter valued at about $32,000. Virtus Investment Advisers LLC increased its position in shares of Dianthus Therapeutics by 7.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock valued at $260,000 after acquiring an additional 416 shares during the last quarter. Royal Bank of Canada raised its holdings in Dianthus Therapeutics by 36.9% during the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after acquiring an additional 542 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.